AIDS: complacency could cause a crisis

Over 50 million people are infected with HIV and the figure is still rising, according to UNAIDS. However, under 30s are continuing to live ignorant of the threat, as a new generation of teenagers has grown up believing that HIV is not something that will affect them. With no cure in sight the Western AIDS crisis may be only just beginning, Datamonitor HIV analyst Dheeraj Khiytani investigates...

Published By Datamonitor

Acute respiratory distress syndrome: searching for effective therapies

Acute respiratory distress syndrome has an annual incidence of up to 75 cases per 100,000 in the US. The condition remains very difficult to treat with a mortality rate between 30% and 60%. Although much research into ARDS has been carried out, the lack of a standard definition for the condition has made trial results unclear, so what hope is there of a treatment breakthrough in the near future?

Published By Datamonitor

Actelion: Tracleer approved for pulmonary hypertension

As the first approved oral medication for PAH, the new drug is likely to be popular among treating physicians and enjoy a rapid uptake. However, while Tracleer may improve patients' symptoms, it is a far cry from a cure for PAH, leaving an effective treatment for PAH a major unmet need in the cardiovascular therapeutics market.

Published By Datamonitor

Abgenix: a new trial for promising cancer drug

Abgenix's drug could have a promising future. If the compound can improve upon the side effect profile of Roche/Genentech's benchmark monoclonal antibody Herceptin (trastuzumab), as well as gaining further indications, it is likely to become a key player within this field of anticancer treatments.

Published By Datamonitor

A new phase in the breast cancer battle?

Published By Datamonitor

A battle looms in mild cognitive impairment...

More than a tenth of the world's elderly people have mild cognitive impairment, representing a significant potential market. Worse, these sufferers have a 50% chance developing Alzheimer's. Although there is no approved treatment available yet, several different therapies are in development. The fight for dominance in this potentially lucrative market is about to begin - but who will win out?

Published By Datamonitor